IL133234A - Hydrogen Tartrate of (R) - 3 (N, N-Dicyclobutyl-Amino) - 8 Fluoro-4,3 Dihydro 1 H2-Benzopyran-5-Carboxamide, process for its preparation and pharmaceutical preparations containing it - Google Patents

Hydrogen Tartrate of (R) - 3 (N, N-Dicyclobutyl-Amino) - 8 Fluoro-4,3 Dihydro 1 H2-Benzopyran-5-Carboxamide, process for its preparation and pharmaceutical preparations containing it

Info

Publication number: IL133234A
Authority: IL; Israel
Prior art keywords: fluoro; dihydro; tartrate; benzopyran; salt
Prior art date: 1997-05-30

Application number

IL13323498A

Other languages

English (en)

Hebrew (he)

Other versions

IL133234A0 (en

Inventor

Hakan Nyqvist

Daniel D Sohn

Original Assignee

Astra Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-05-30

Filing date

1998-05-15

Publication date

2004-05-12

1998-05-15 Application filed by Astra Ab filed Critical Astra Ab

2001-03-19 Publication of IL133234A0 publication Critical patent/IL133234A0/xx

2004-05-12 Publication of IL133234A publication Critical patent/IL133234A/en

Links

238000000034 method Methods 0.000 title claims description 14
239000008194 pharmaceutical composition Substances 0.000 title description 4
238000002360 preparation method Methods 0.000 title description 4
150000003839 salts Chemical class 0.000 claims abstract description 24
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 17
239000001257 hydrogen Substances 0.000 claims abstract description 17
229940095064 tartrate Drugs 0.000 claims description 25
238000004519 manufacturing process Methods 0.000 claims description 15
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 14
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
239000003960 organic solvent Substances 0.000 claims description 11
239000003814 drug Substances 0.000 claims description 5
238000010438 heat treatment Methods 0.000 claims description 5
239000011356 non-aqueous organic solvent Substances 0.000 claims description 4
208000024827 Alzheimer disease Diseases 0.000 claims description 3
239000002253 acid Substances 0.000 claims description 3
208000019901 Anxiety disease Diseases 0.000 claims description 2
206010046543 Urinary incontinence Diseases 0.000 claims description 2
230000036506 anxiety Effects 0.000 claims description 2
208000010877 cognitive disease Diseases 0.000 claims description 2
239000002904 solvent Substances 0.000 claims description 2
230000002265 prevention Effects 0.000 claims 4
-1 hydrogen (2R, 3R)-tartrate Chemical class 0.000 abstract description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
150000004682 monohydrates Chemical class 0.000 description 15
239000000243 solution Substances 0.000 description 11
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
239000004480 active ingredient Substances 0.000 description 9
239000003826 tablet Substances 0.000 description 9
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 8
239000001828 Gelatine Substances 0.000 description 8
229920000159 gelatin Polymers 0.000 description 8
235000019322 gelatine Nutrition 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
239000002775 capsule Substances 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
239000000203 mixture Substances 0.000 description 6
QRAOZQGIUIDZQZ-UHFFFAOYSA-N 4-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1,4-benzoxazine Chemical compound C=1C=C2N(C)CCOC2=CC=1B1OC(C)(C)C(C)(C)O1 QRAOZQGIUIDZQZ-UHFFFAOYSA-N 0.000 description 5
239000013078 crystal Substances 0.000 description 5
238000001179 sorption measurement Methods 0.000 description 5
150000003892 tartrate salts Chemical class 0.000 description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
238000003795 desorption Methods 0.000 description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
239000007787 solid Substances 0.000 description 4
238000003860 storage Methods 0.000 description 4
239000011975 tartaric acid Substances 0.000 description 4
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
238000009472 formulation Methods 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
238000007865 diluting Methods 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
239000008187 granular material Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
239000000047 product Substances 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
201000000980 schizophrenia Diseases 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
230000004580 weight loss Effects 0.000 description 2
UUDLQDCYDSATCH-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;hydrate Chemical compound O.OC(=O)C(O)C(O)C(O)=O UUDLQDCYDSATCH-UHFFFAOYSA-N 0.000 description 1
102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 1
101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
229920000945 Amylopectin Polymers 0.000 description 1
101100438156 Arabidopsis thaliana CAD7 gene Proteins 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
208000032841 Bulimia Diseases 0.000 description 1
206010006550 Bulimia nervosa Diseases 0.000 description 1
BISJICQYOHMDEQ-UHFFFAOYSA-N C(=O)(O)C(O)C(O)C(=O)O.O1CC=CC=2C1=CC=CC2C(=O)N Chemical compound C(=O)(O)C(O)C(O)C(=O)O.O1CC=CC=2C1=CC=CC2C(=O)N BISJICQYOHMDEQ-UHFFFAOYSA-N 0.000 description 1
101150071647 CAD4 gene Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
101100322652 Catharanthus roseus ADH13 gene Proteins 0.000 description 1
101100087088 Catharanthus roseus Redox1 gene Proteins 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical compound OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
239000005662 Paraffin oil Substances 0.000 description 1
206010036618 Premenstrual syndrome Diseases 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
238000005266 casting Methods 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
235000013681 dietary sucrose Nutrition 0.000 description 1
238000000113 differential scanning calorimetry Methods 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
210000005095 gastrointestinal system Anatomy 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
239000010439 graphite Substances 0.000 description 1
229910002804 graphite Inorganic materials 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
230000036512 infertility Effects 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
238000000275 quality assurance Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
239000012439 solid excipient Substances 0.000 description 1
239000012265 solid product Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
238000011146 sterile filtration Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000001331 thermoregulatory effect Effects 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
235000010215 titanium dioxide Nutrition 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrane Compounds (AREA)

IL13323498A 1997-05-30 1998-05-15 Hydrogen Tartrate of (R) - 3 (N, N-Dicyclobutyl-Amino) - 8 Fluoro-4,3 Dihydro 1 H2-Benzopyran-5-Carboxamide, process for its preparation and pharmaceutical preparations containing it IL133234A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9702066A SE510305C2 (sv)	1997-05-30	1997-05-30	Nytt salt
PCT/SE1998/000907 WO1998054166A1 (en)	1997-05-30	1998-05-15	A new salt

Publications (2)

Publication Number	Publication Date
IL133234A0 IL133234A0 (en)	2001-03-19
IL133234A true IL133234A (en)	2004-05-12

Family

ID=20407187

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL13323498A IL133234A (en)	1997-05-30	1998-05-15	Hydrogen Tartrate of (R) - 3 (N, N-Dicyclobutyl-Amino) - 8 Fluoro-4,3 Dihydro 1 H2-Benzopyran-5-Carboxamide, process for its preparation and pharmaceutical preparations containing it

Country Status (33)

Country	Link
US (2)	US6858645B2 (xx)
EP (1)	EP0984952B1 (xx)
JP (1)	JP3554338B2 (xx)
KR (1)	KR20010013127A (xx)
CN (1)	CN1198814C (xx)
AR (1)	AR012751A1 (xx)
AT (1)	ATE228121T1 (xx)
AU (1)	AU729301B2 (xx)
BG (1)	BG64051B1 (xx)
BR (1)	BR9809519A (xx)
CA (1)	CA2291732C (xx)
DE (1)	DE69809547T2 (xx)
DK (1)	DK0984952T3 (xx)
EE (1)	EE03874B1 (xx)
ES (1)	ES2187030T3 (xx)
HU (1)	HUP0001878A3 (xx)
ID (1)	ID23794A (xx)
IL (1)	IL133234A (xx)
IS (1)	IS1943B (xx)
MY (1)	MY117960A (xx)
NO (1)	NO995853L (xx)
NZ (1)	NZ501075A (xx)
PL (1)	PL337181A1 (xx)
PT (1)	PT984952E (xx)
RU (1)	RU2193560C2 (xx)
SE (1)	SE510305C2 (xx)
SK (1)	SK282755B6 (xx)
TR (1)	TR199902926T2 (xx)
TW (1)	TW510899B (xx)
UA (1)	UA53720C2 (xx)
WO (1)	WO1998054166A1 (xx)
YU (1)	YU62499A (xx)
ZA (1)	ZA984486B (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0102886D0 (sv) *	2001-08-29	2001-08-29	Astrazeneca Ab	New formulation
SE0102887D0 (sv) *	2001-08-29	2001-08-29	Astrazeneca Ab	New formulation
SE0102888D0 (sv) *	2001-08-29	2001-08-29	Astrazeneca Ab	New formulation
CA2494687A1 (en) *	2002-08-15	2004-02-26	Wyeth	Agonism of the 5ht2a receptor for treatment of thermoregulatory dysfunction
SE0301796D0 (sv) *	2003-06-19	2003-06-19	Astrazeneca Ab	New use II
SE0301795D0 (sv) *	2003-06-19	2003-06-19	Astrazeneca Ab	New use I
ATE528807T1 (de) *	2006-05-11	2011-10-15	Johnson Controls Saft Advanced Power Solutions Llc	Modulares batteriesystem
JP5163931B2 (ja) *	2007-03-08	2013-03-13	株式会社リコー	定着装置及び画像形成装置
EP2065385A1 (en) *	2007-11-28	2009-06-03	Laboratorios SALVAT, S.A.	Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
CN103833712B (zh) *	2008-11-28	2016-02-03	中国医学科学院药物研究所	硝克柳胺化合物晶ii型、其制法和其药物组合物与用途
DK2989095T3 (en) *	2013-04-26	2019-03-18	Sanofi Sa	TARTRATE SALT OF 5-CHLORTHIOPHEN-2-CARBOXYLIC ACID [(S) -2- [METHYL-3- (2-OXOPYRROLIDIN-1-YL) -BENZENESULPHONYLAMINO] -3- (4-METHYLPIPERAZIN-1-YL) -3-OX AMID

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU611976B2 (en) *	1987-12-24	1991-06-27	John Wyeth & Brother Limited	Aroyl urea and carbamic acid derivatives of azabicyclo compounds
US5420151A (en) *	1989-12-22	1995-05-30	Aktiebolaget Astra	Chroman derivatives
US5616610A (en)	1989-12-22	1997-04-01	Astra Aktiebolag	(R)-5-carbamoyl-8-fluoro-3-N,N-disubstituted-amino-3,4-dihydro-2H-1-benzopyrans
RU2047614C1 (ru) *	1992-06-15	1995-11-10	Джон Вайс энд Бразер Лимитед	Гетероциклические соединения, или их фармацевтически приемлемые аддитивные соли кислоты, или n-оксид гетероциклического соединения, или его аддитивная соль кислоты
US5990114A (en)	1996-02-28	1999-11-23	Recordati, S.A., Chemical And Pharmaceutical Company	Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence
IT1282705B1 (it)	1996-02-28	1998-03-31	Recordati Chem Pharm	Uso di antagonisti del recettore serotoninergico 5-ht\|a per il trattamento dell'incontinenza urinaria

1997
- 1997-05-30 SE SE9702066A patent/SE510305C2/sv not_active IP Right Cessation
1998
- 1998-05-13 TW TW087107397A patent/TW510899B/zh active
- 1998-05-15 JP JP50056099A patent/JP3554338B2/ja not_active Expired - Fee Related
- 1998-05-15 AT AT98925993T patent/ATE228121T1/de not_active IP Right Cessation
- 1998-05-15 NZ NZ501075A patent/NZ501075A/en unknown
- 1998-05-15 EE EEP199900549A patent/EE03874B1/xx not_active IP Right Cessation
- 1998-05-15 DK DK98925993T patent/DK0984952T3/da active
- 1998-05-15 PL PL98337181A patent/PL337181A1/xx unknown
- 1998-05-15 CA CA002291732A patent/CA2291732C/en not_active Expired - Fee Related
- 1998-05-15 UA UA99127241A patent/UA53720C2/uk unknown
- 1998-05-15 US US09/077,718 patent/US6858645B2/en not_active Expired - Fee Related
- 1998-05-15 ID IDW991407A patent/ID23794A/id unknown
- 1998-05-15 SK SK1594-99A patent/SK282755B6/sk unknown
- 1998-05-15 TR TR1999/02926T patent/TR199902926T2/xx unknown
- 1998-05-15 EP EP98925993A patent/EP0984952B1/en not_active Expired - Lifetime
- 1998-05-15 ES ES98925993T patent/ES2187030T3/es not_active Expired - Lifetime
- 1998-05-15 HU HU0001878A patent/HUP0001878A3/hu unknown
- 1998-05-15 AU AU77923/98A patent/AU729301B2/en not_active Ceased
- 1998-05-15 YU YU62499A patent/YU62499A/sh unknown
- 1998-05-15 WO PCT/SE1998/000907 patent/WO1998054166A1/en not_active Ceased
- 1998-05-15 RU RU99128026/04A patent/RU2193560C2/ru not_active IP Right Cessation
- 1998-05-15 BR BR9809519-6A patent/BR9809519A/pt not_active IP Right Cessation
- 1998-05-15 PT PT98925993T patent/PT984952E/pt unknown
- 1998-05-15 IL IL13323498A patent/IL133234A/en not_active IP Right Cessation
- 1998-05-15 CN CNB988056631A patent/CN1198814C/zh not_active Expired - Fee Related
- 1998-05-15 DE DE69809547T patent/DE69809547T2/de not_active Expired - Fee Related
- 1998-05-15 KR KR19997011107A patent/KR20010013127A/ko not_active Abandoned
- 1998-05-26 ZA ZA984486A patent/ZA984486B/xx unknown
- 1998-05-26 AR ARP980102434A patent/AR012751A1/es unknown
- 1998-05-29 MY MYPI98002400A patent/MY117960A/en unknown
1999
- 1999-11-24 IS IS5270A patent/IS1943B/is unknown
- 1999-11-29 NO NO995853A patent/NO995853L/no not_active Application Discontinuation
- 1999-12-03 BG BG103949A patent/BG64051B1/bg unknown
2004
- 2004-10-12 US US10/964,388 patent/US20050085532A1/en not_active Abandoned

Also Published As

Publication number	Publication date
SK282755B6 (sk)	2002-12-03
SE9702066L (sv)	1998-12-01
ES2187030T3 (es)	2003-05-16
CN1198814C (zh)	2005-04-27
PT984952E (pt)	2003-03-31
SE510305C2 (sv)	1999-05-10
SE9702066D0 (sv)	1997-05-30
ID23794A (id)	2000-05-11
NZ501075A (en)	2001-08-31
NO995853L (no)	2000-01-31
EE03874B1 (et)	2002-10-15
RU2193560C2 (ru)	2002-11-27
TW510899B (en)	2002-11-21
JP3554338B2 (ja)	2004-08-18
EP0984952A1 (en)	2000-03-15
BR9809519A (pt)	2000-06-20
DE69809547T2 (de)	2003-08-21
SK159499A3 (en)	2000-10-09
US20050085532A1 (en)	2005-04-21
KR20010013127A (ko)	2001-02-26
JP2002501527A (ja)	2002-01-15
CN1258290A (zh)	2000-06-28
EP0984952B1 (en)	2002-11-20
ZA984486B (en)	1998-11-30
NO995853D0 (no)	1999-11-29
US6858645B2 (en)	2005-02-22
WO1998054166A1 (en)	1998-12-03
MY117960A (en)	2004-08-30
IS5270A (is)	1999-11-24
BG64051B1 (bg)	2003-11-28
CA2291732C (en)	2003-12-30
ATE228121T1 (de)	2002-12-15
HK1025575A1 (en)	2000-11-17
EE9900549A (et)	2000-06-15
HUP0001878A2 (hu)	2001-05-28
US20030109576A1 (en)	2003-06-12
AR012751A1 (es)	2000-11-08
DE69809547D1 (de)	2003-01-02
YU62499A (sh)	2002-06-19
BG103949A (en)	2000-07-31
IL133234A0 (en)	2001-03-19
TR199902926T2 (xx)	2000-03-21
AU7792398A (en)	1998-12-30
AU729301B2 (en)	2001-02-01
IS1943B (is)	2004-08-13
CA2291732A1 (en)	1998-12-03
HUP0001878A3 (en)	2002-04-29
DK0984952T3 (da)	2003-02-24
PL337181A1 (en)	2000-08-14
UA53720C2 (uk)	2003-02-17

Publication	Publication Date	Title
JP5086069B2 (ja)	2012-11-28	重硫酸アタザナビルおよび新規形態の製造方法
KR20180030964A (ko)	2018-03-27	이브루티닙과 카복실산의 공결정체
EP0984952B1 (en)	2002-11-20	A new salt
JP2021035967A (ja)	2021-03-04	（ｓ）−［３，４−ジフルオロ−２−（２−フルオロ−４−ヨードフェニルアミノ）フェニル］［３−ヒドロキシ−３−（ピペリジン−２−イル）アゼチジン−１−イル］−メタノンの結晶性フマル酸塩
CA3255323A1 (en)	2023-10-05	5-MEO-DMT CRYSTALLINE HYDROBROMIDE SALT
CN118201927A (zh)	2024-06-14	戊二酸利那拉赞的盐酸盐的多晶型物
EP3398946B1 (en)	2022-05-04	Salt of morpholine derivative and crystalline form thereof, as well as preparation method, pharmaceutical composition and use of the same
KR101557832B1 (ko)	2015-10-06	(ｒ)-3-플루오로페닐-3,4,5-트리플루오로벤질카르밤산 1-아자비시클로 [2.2.2]옥트-3-일 에스테르의 안정한 결정성 염
JP5959617B2 (ja)	2016-08-02	オタミキサバンの安息香酸塩
JP2025539208A (ja)	2025-12-03	プロキシモドの結晶形およびその調製方法と使用
HK1025575B (en)	2003-05-16	A new salt
TW202216726A (zh)	2022-05-01	八氫噻吩并喹啉化合物之琥珀酸鹽及其結晶
EP1515959B1 (en)	2009-08-12	Pharmaceutical salts of reboxetine
MXPA99010942A (en)	2000-09-04	A new salt
CZ426199A3 (cs)	2000-05-17	Nová sůl
AU2022412842B2 (en)	2025-11-27	Novel acid addition salt and crystalline form of (2r,3s)-2-(3-(4,5-dichloro-1h-benzo[d]imidazol-1-yl)propyl)piperidin-3-ol
CA3080657A1 (en)	2019-05-09	Crystalline salt of a tricyclic poly(adp-ribose) polymerase inhibitor
AU2023253008A1 (en)	2024-11-07	Polymorph of 7,8-dihydroxyflavone, and preparation method therefor
CN115124456A (zh)	2022-09-30	哌马色林药用盐、制备方法、含其的药物组合物及应用
EP3976598A1 (en)	2022-04-06	Selective histamine h3 antagonist acid addition salts and process for the preparation thereof

Legal Events

Date	Code	Title	Description
2004-09-27	FF	Patent granted
2009-07-20	MM9K	Patent not in force due to non-payment of renewal fees